Health
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Business Wire
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a s
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure…
-
General23 hours agoQantas terminal at Melbourne Airport evacuated and flights delayed due to fire
-
General20 hours agoHome of Andrii Yermak, Zelenskyy’s chief of staff, raided by anti-corruption unit
-
General9 hours agoProtecting victims of explicit AI content online
-
Business12 hours agoIs this the best ASX ETF to diversify your portfolio with?